← Back to Search

Chronic Disease Self-Management Program for Systemic Lupus Erythematosus (WELL Trial)

N/A
Waitlist Available
Led By Cristina M Drenkard, MD, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

WELL Trial Summary

This trial will study whether the CDSMP can help African American women with SLE to better manage their condition and improve their health outcomes.

Who is the study for?
This study is specifically for African American women who are already part of the GOAL study and have systemic lupus erythematosus (SLE). It's not open to those who've done the Chronic Disease Self-Management Program in the last five years or have significant cognitive impairment.Check my eligibility
What is being tested?
The trial is testing if a program called Chronic Disease Self-Management Program can help improve health outcomes and reduce healthcare usage for African American women with SLE, as it hasn't been widely studied in this group before.See study design
What are the potential side effects?
Since CDSMP is an educational program rather than a medication, there aren't typical drug side effects. However, participants may experience stress or discomfort when discussing personal health issues.

WELL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Communication With Physician - Stanford 3Q Scale Score
PROMIS Ability to Participate in Social Roles and Activities Score
PROMIS Anxiety Score
+7 more
Secondary outcome measures
Emergency Department Visit Rate
Hospitalization Rate
Number of Participants at Each Activation Level of the Patient Activation Measure (PAM-10)
+3 more

WELL Trial Design

2Treatment groups
Active Control
Group I: Chronic Disease Self-management Program (CDSMP)Active Control1 Intervention
A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
Group II: Usual CareActive Control1 Intervention
African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,636 Previous Clinical Trials
2,559,874 Total Patients Enrolled
National Institute on Minority Health and Health Disparities (NIMHD)NIH
380 Previous Clinical Trials
1,214,955 Total Patients Enrolled
Centers for Disease Control and PreventionFED
875 Previous Clinical Trials
22,476,703 Total Patients Enrolled

Media Library

Chronic Disease Self-Management Program (CDSMP) Clinical Trial Eligibility Overview. Trial Name: NCT02988661 — N/A
Systemic Lupus Erythematosus Research Study Groups: Chronic Disease Self-management Program (CDSMP), Usual Care
Systemic Lupus Erythematosus Clinical Trial 2023: Chronic Disease Self-Management Program (CDSMP) Highlights & Side Effects. Trial Name: NCT02988661 — N/A
Chronic Disease Self-Management Program (CDSMP) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02988661 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Lupus Science & MedicineJournal
Overcoming Barriers to Recruitment and Retention of African–american Women with SLE in Behavioural Interventions: Lessons Learnt from the WELL Study
Drenkard, Cristina, Kirk Easley, Gaobin Bao, Charmayne Dunlop-Thomas, S Sam Lim, and Teresa Brady. 2020. “Overcoming Barriers to Recruitment and Retention of African–american Women with SLE in Behavioural Interventions: Lessons Learnt from the WELL Study”. Lupus Science & Medicine. BMJ. doi:10.1136/lupus-2020-000391.
Arthritis Research & TherapyJournal
Health Service Utilization Among African American Women Living with Systemic Lupus Erythematosus: Perceived Impacts of a Self-management Intervention
Twumasi, Abena A., Anna Shao, Charmayne Dunlop-Thomas, Cristina Drenkard, and Hannah L. F. Cooper. 2019. “Health Service Utilization Among African American Women Living with Systemic Lupus Erythematosus: Perceived Impacts of a Self-management Intervention”. Arthritis Research & Therapy. Springer Science and Business Media LLC. doi:10.1186/s13075-019-1942-7.
clinicaltrials.govStudy
Women Empowered to Live With Lupus Study
Cristina M Drenkard 2017. "Women Empowered to Live With Lupus Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02988661.
All > Systemic Lupus Erythematosus > Lupus
~85 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top